Molecular Signatures of Amyotrophic Lateral Sclerosis in Skeletal Muscle
骨骼肌肌萎缩侧索硬化症的分子特征
基本信息
- 批准号:8722055
- 负责人:
- 金额:$ 18.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2015-09-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAmyotrophic Lateral SclerosisArchivesAtrophicBiological MarkersBiopsy SpecimenCessation of lifeClinicClinicalClinical ResearchClinical TrialsConsensusDataDegenerative DisorderDetectionDiagnosisDiseaseDisease ManagementDisease ProgressionEarly DiagnosisEducational workshopEnrollmentFiberFundingGene Expression ProfileGoalsHistologyInterventionLaboratoriesMessenger RNAMolecularMolecular ProfilingMolecular TargetMonitorMotor NeuronsMusMuscleMuscle WeaknessNeurodegenerative DisordersNeuromuscular DiseasesNeuromuscular JunctionOrganParalysedPatientsPatternPharmaceutical PreparationsPhasePositioning AttributeProcessProtein IsoformsProteinsResearch PersonnelSamplingSequence AnalysisSkeletal MuscleSpecificityStagingTestingTimeTissuesTreatment EfficacyVariantWorkbaseclinical Diagnosiscohortdeep sequencingdisease diagnosisdisorder controleffective therapyimprovedmitochondrial dysfunctionmouse modelneuromuscularnext generationnovelnovel therapeuticspatient populationpre-clinicalprotein expressionpublic health relevancetool
项目摘要
DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a degenerative disease of motor neurons that inexorably leads to progressive weakness and death. There is no specific biomarker for this disease, and the diagnosis is often delayed as clinical and electrophysiological examinations are often inconclusive in the early stages. Furthermore, once a diagnosis is established, the current tools to track patients are insensitive for the timely detection of disease improvement or worsening. A biomarker that can facilitate diagnosis, track disease progression, or both, would fill a large clinical gap in ALS management, and expedite clinical trials of novel therapies. The long term goal of this application is to identify molecular
signatures in muscle of ALS patients that can serve as disease biomarkers. In ALS, changes occur in skeletal muscle prior to motor neuron death and clinical onset, such as structural changes in the neuromuscular junction, muscle restricted mitochondrial dysfunction, and fiber atrophy. Muscle is the "end organ" affected by the degenerative process of ALS and is the most accessible for molecular study. Here we hypothesize that gene expression patterns in muscle from patients with ALS contain molecular signatures that can serve as biomarkers of the disease. This hypothesis is based on preliminary data we obtained using next generation deep sequencing on muscle samples of clinically well characterized ALS patients. Using non-ALS disease- and normal control samples, we identified over 300 unique targets in ALS samples, including isoform variances, that will serve as the basis of study for this application. We are wel positioned to carry out this study because of the large neuromuscular patient population, including ALS and ALS mimics, and our oversight of the electrodiagnostic and muscle histology laboratories. Here, we will further investigate our molecular targets with the following two specific aims: Specific Aims: 1. To validate ALS-specific targets and isoform variances identified by deep sequencing by performing PCR analysis of a large cohort of ALS and non-ALS muscle samples. 2: To assess protein expression of validated targets in muscle tissues from ALS patients and correlate targets with muscle samples from the G93A SOD1 ALS mouse.
描述(由申请人提供):肌萎缩侧索硬化症(ALS)是一种运动神经元退行性疾病,可导致进行性虚弱和死亡。这种疾病没有特异性的生物标志物,并且由于临床和电生理检查在早期阶段通常不确定,因此诊断通常被延迟。此外,一旦确定诊断,当前用于跟踪患者的工具对于及时检测疾病改善或恶化不敏感。一种可以促进诊断、跟踪疾病进展或两者兼而有之的生物标志物将填补ALS管理中的巨大临床空白,并加快新疗法的临床试验。本申请的长期目标是鉴定分子
肌萎缩侧索硬化症患者肌肉中的特征可以作为疾病生物标志物。在ALS中,在运动神经元死亡和临床发作之前骨骼肌发生变化,例如神经肌肉接头的结构变化、肌肉限制性线粒体功能障碍和纤维萎缩。肌肉是受ALS退行性过程影响的“终末器官”,并且是最容易进行分子研究的。在这里,我们假设肌萎缩侧索硬化症患者肌肉中的基因表达模式包含可以作为该疾病生物标志物的分子特征。这一假设是基于我们使用下一代深度测序对临床特征良好的ALS患者的肌肉样本获得的初步数据。使用非ALS疾病和正常对照样品,我们在ALS样品中鉴定了300多个独特的靶标,包括同种型差异,这将作为本申请的研究基础。我们很好地进行这项研究,因为大量的神经肌肉患者群体,包括ALS和ALS模拟,以及我们对电诊断和肌肉组织学实验室的监督。在这里,我们将进一步研究我们的分子靶点,有以下两个具体目标:具体目标:1。通过对大量ALS和非ALS肌肉样本进行PCR分析,验证通过深度测序鉴定的ALS特异性靶标和亚型差异。第二章:评估ALS患者肌肉组织中经验证靶标的蛋白质表达,并将靶标与G93A SOD1 ALS小鼠肌肉样本相关联。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER H KING其他文献
PETER H KING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER H KING', 18)}}的其他基金
Therapeutic benefit of targeting neuroinflammation in spinal cord injury with a novel small molecule inhibitor of the RNA regulator HuR
使用 RNA 调节因子 HuR 的新型小分子抑制剂针对脊髓损伤中的神经炎症的治疗益处
- 批准号:
10472150 - 财政年份:2022
- 资助金额:
$ 18.19万 - 项目类别:
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression
小胶质细胞 Hur 在促进神经炎症和 ALS 疾病进展中的作用
- 批准号:
9559943 - 财政年份:2018
- 资助金额:
$ 18.19万 - 项目类别:
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression
小胶质细胞 Hur 在促进神经炎症和 ALS 疾病进展中的作用
- 批准号:
10421258 - 财政年份:2018
- 资助金额:
$ 18.19万 - 项目类别:
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression
小胶质细胞 Hur 在促进神经炎症和 ALS 疾病进展中的作用
- 批准号:
10046279 - 财政年份:2018
- 资助金额:
$ 18.19万 - 项目类别:
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS
骨骼肌中的 Smad 信号转导作为 ALS 疾病进展的生物标志物
- 批准号:
9222815 - 财政年份:2016
- 资助金额:
$ 18.19万 - 项目类别:
HuR and RNA regulation as a Novel Therapeutic Target in Malignant Glioma
HuR 和 RNA 调控作为恶性胶质瘤的新治疗靶点
- 批准号:
9257249 - 财政年份:2014
- 资助金额:
$ 18.19万 - 项目类别:
Molecular Signatures of Amyotrophic Lateral Sclerosis in Skeletal Muscle
骨骼肌肌萎缩侧索硬化症的分子特征
- 批准号:
8619114 - 财政年份:2013
- 资助金额:
$ 18.19万 - 项目类别:
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue
ALS 中生存因子的 RNA 靶向失调:HuR 来拯救
- 批准号:
8242240 - 财政年份:2012
- 资助金额:
$ 18.19万 - 项目类别:
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue
ALS 中生存因子的 RNA 靶向失调:HuR 来拯救
- 批准号:
8774160 - 财政年份:2012
- 资助金额:
$ 18.19万 - 项目类别:
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue
ALS 中生存因子的 RNA 靶向失调:HuR 来拯救
- 批准号:
8413600 - 财政年份:2012
- 资助金额:
$ 18.19万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 18.19万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 18.19万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 18.19万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 18.19万 - 项目类别:
Fellowship